Wasatch Advisors LP Has $95.17 Million Holdings in Certara, Inc. (NASDAQ:CERT)

Wasatch Advisors LP reduced its holdings in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 0.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,935,998 shares of the company's stock after selling 79,943 shares during the period. Wasatch Advisors LP owned about 5.55% of Certara worth $95,168,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Kopion Asset Management LLC increased its stake in shares of Certara by 46.0% during the fourth quarter. Kopion Asset Management LLC now owns 555,643 shares of the company's stock worth $5,918,000 after buying an additional 175,005 shares during the period. Principal Financial Group Inc. raised its holdings in shares of Certara by 3.1% in the 4th quarter. Principal Financial Group Inc. now owns 531,445 shares of the company's stock valued at $5,660,000 after purchasing an additional 15,739 shares in the last quarter. Vontobel Holding Ltd. acquired a new stake in Certara in the fourth quarter valued at $1,295,000. Barclays PLC increased its holdings in shares of Certara by 198.3% in the 3rd quarter. Barclays PLC now owns 70,525 shares of the company's stock valued at $825,000 after acquiring an additional 46,880 shares during the last quarter. Finally, Proficio Capital Partners LLC purchased a new stake in Certara during the fourth quarter worth approximately $148,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on CERT shares. TD Cowen assumed coverage on Certara in a report on Thursday, February 27th. They set a "buy" rating and a $16.00 price objective on the stock. Stephens reissued an "overweight" rating and set a $17.00 price objective on shares of Certara in a report on Thursday, February 27th. Robert W. Baird lifted their price objective on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Barclays lowered their price objective on Certara from $13.00 to $11.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Finally, William Blair reiterated a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.17.

Certara Stock Performance

Certara stock traded down $0.13 during mid-day trading on Monday, reaching $14.02. The company's stock had a trading volume of 498,673 shares, compared to its average volume of 1,185,977. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a twelve month low of $8.64 and a twelve month high of $17.94. The business has a 50 day moving average price of $11.62 and a 200-day moving average price of $11.47. The firm has a market cap of $2.26 billion, a price-to-earnings ratio of -70.10, a PEG ratio of 9.29 and a beta of 1.64.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.